Triplet Chemotherapy with Cisplatin versus Oxaliplatin in the CRITICS Trial: Treatment Compliance, Toxicity, Outcomes and Quality of Life in Patients with Resectable Gastric Cancer.

Cancers (Basel) · 2022 · PMC9221508 · PMID 35740628

Europe PMC DOI

hedged sentence

0.1260

closest p · 2.5× alpha

0.1260

boldest claim

The sentences

did not reach statistical significancep = 0.126not close (p > 0.1)

Good histopathological response was slightly more often achieved in the ECX group, although this did not reach statistical significance: 94 (21%) for patients who received preoperative ECX compared to 16 (15%) patients who received preoperative EOX ( p = 0.126) (OR 0.64 (95% CI 0.36–1.14) ( p = 0.128).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.